REFERENCES

1. Cacabelos R. World Guide for Drug Use and Pharmacogenomics. EuroEspes Publishing Co.; Corunna, 2012.

2. Cacabelos R. Pharmacoepigenetics. Academic Press/Elsevier; San Diego, 2019.

3. Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol 2019;12:407-42.

4. Obeng A, El Rouby N, Liu M, Wallsten R. Important preparatory steps and clinical considerations for pharmacogenetics adoption into practice. J Transl Genet Genom 2020:4.

5. Pandey A, Estepp JH, Ramkrishna D. Hydroxyurea treatment of sickle cell disease: towards a personalized model-based approach. J Transl Genet Genom 2021:5.

6. Genvigir FDV, Cerda A, Hirata TDC, Hirata MH, Hirata RDC. Mycophenolic acid pharmacogenomics in kidney transplantation. J Transl Genet Genom 2020;4:320-55.

7. Amadori E, Brolatti N, Scala M, et al. Precision medicine in early-onset epilepsy: the KCNQ2 paradigm. J Transl Genet Genom 2020;4:278-84.

8. Seguí HA, Melin K, Quiñones DS, Duconge J. A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. J Transl Genet Genom 2020;4:263-77.

9. Lu DY, Wu HY, Cao S, Che JY. Historical analysis of suicide. J Transl Genet Genom 2020;4:203-9.

10. Cacabelos R. Population-level pharmacogenomics for precision drug development in dementia. Expert Rev Precis Med Drug Dev 2018;3:163-88.